Acquired Resistance Is Oncogene and Drug Agnostic

Publication date: 14 October 2019Source: Cancer Cell, Volume 36, Issue 4Author(s): Robert C. DoebeleRecent approvals of TRK inhibitors have demonstrated the success of a tumor agnostic approach to oncogene-targeted therapy across cancers. Collective data from acquired resistance studies suggest that resistance mechanisms, which include both kinase domain mutations and bypass signaling via RTK-RAS-RAF-MAPK pathways, frequently recur regardless of tumor type, oncogene, and drug.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research